Delivery Order SPE2DB20D1100-SPE2DB25FE1R7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $27,766.85 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 12, 2025, with an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,812.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and carries an ultimate completion date of July 22, 2025. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $4,328.04 under firm fixed-price terms, with an ultimate completion date of July 31, 2025. The pharmaceutical products will be delivered to the contracting location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $35,913.34 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count) on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order was issued with no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance, which aligns with the contractor's corporate headquarters location. The award represents a...
- The Defense Logistics Agency awarded a $3,503.92 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price, non-set-aside contract is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp fulfills this delivery order as part of its broader federal medical supply obligations...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,882.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded and completed on August 8, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $8,962.67 under a firm fixed price structure, with an ultimate completion date of August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,238.80 to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order carries no set-aside designation and was competitively awarded. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Ondansetron is an antiemetic medication commonly used to prevent nausea...
- The Defense Logistics Agency awarded a delivery order valued at $28,026.72 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count packages). This competitively awarded, firm fixed price delivery order was issued on August 12, 2025, with an ultimate completion date of August 13, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1R7Delivery Order
The Defense Logistics Agency awarded a $17,662.48 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count package) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitive, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a potential value of $999,999,999.00 and extends through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supplies a comprehensive portfolio of medical products to support military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. Ondansetron, an antiemetic medication commonly used in medical settings, represents one component of the company's extensive pharmaceutical delivery capability under its prime vendor agreement. This delivery order demonstrates the operational execution of the broader IDC vehicle, which enables DLA to procure pharmaceutical products, specialty medications, vaccines, and medical supplies globally to support Defense Health Agency operations and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.7k | 8/19/25 |